Literature DB >> 15457501

Relationship between dopaminergic neurotransmission, alcoholism, and Reward Deficiency syndrome.

Abdalla Bowirrat1, Marlene Oscar-Berman.   

Abstract

In this review, we described the neural substrates underlying Reward Deficiency syndrome which, in turn, is posited to underlie alcohol dependency. Alcoholism is a complex, multifactorial disorder that results from the interplay between genetic and environmental factors. The D(2) dopamine receptor (DRD(2)) has been associated with pleasure, and the DRD(2) A1 allele has been referred to as a reward gene. Evidence suggests that there is a tripartite interaction involving dopamine receptor deficiency, a propensity to abuse alcohol, and reduced sensitivity to rewards. This interaction relies heavily on genetic characteristics of the individual, with certain ethnic groups having a greater tendency toward alcoholism than others. The DRD(2) has been one of the most widely studied in neuropsychiatric disorders in general, and in alcoholism and other addictions in particular. The dopamine D2 (DRD2) gene, and especially its allele TaqI A1 allele and its receptor, also may be involved in comorbid antisocial personality disorder symptoms, high novelty seeking, and related traits. The mesocorticolimbic dopaminergic pathway system plays an especially important role in mediating reinforcement by abused drugs, and it may be a common denominator for addictions such as alcoholism. When the mesocorticolimbic dopamine reward system dysfunctions (perhaps caused by certain genetic variants), the end result is Reward Deficiency syndrome and subsequent drug-seeking behaviors. Reward Deficiency syndrome refers to the breakdown of the reward cascade, and resultant aberrant conduct, due to genetic and environmental influences. Alcohol and other drugs of abuse, as well as most positive reinforcers, cause activation and neuronal release of brain dopamine, which can decrease negative feelings and satisfy abnormal cravings. A deficiency or absence of DRD(2) receptors then predisposes individuals to a high risk for multiple addictive, impulsive, and compulsive behaviors. Although other neurotransmitters (e.g., glutamate, gamma-aminobutyric acid (GABA), and serotonin) may be important in determining the rewarding and stimulating effects of ethanol, dopamine may be critical for initiating drug use and for reinstating drug use during protracted abstinence. This article contains supplementary material, which may be viewed at the American Journal of Medical Genetics website at http://www.interscience.wiley.com/jpages/0148-7299:1/suppmat/index.html. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15457501     DOI: 10.1002/ajmg.b.30080

Source DB:  PubMed          Journal:  Am J Med Genet B Neuropsychiatr Genet        ISSN: 1552-4841            Impact factor:   3.568


  97 in total

1.  Synchrony of corticostriatal-midbrain activation enables normal inhibitory control and conflict processing in recovering alcoholic men.

Authors:  Tilman Schulte; Eva M Müller-Oehring; Edith V Sullivan; Adolf Pfefferbaum
Journal:  Biol Psychiatry       Date:  2011-12-02       Impact factor: 13.382

2.  Exploring potential sources of differential vulnerability and susceptibility in risk from environmental hazards to expand the scope of risk assessment.

Authors:  Joel Schwartz; David Bellinger; Thomas Glass
Journal:  Am J Public Health       Date:  2011-10-20       Impact factor: 9.308

Review 3.  Function and dysfunction of prefrontal brain circuitry in alcoholic Korsakoff's syndrome.

Authors:  Marlene Oscar-Berman
Journal:  Neuropsychol Rev       Date:  2012-04-27       Impact factor: 7.444

Review 4.  Neuropsychopharmacology and neurogenetic aspects of executive functioning: should reward gene polymorphisms constitute a diagnostic tool to identify individuals at risk for impaired judgment?

Authors:  Abdalla Bowirrat; Thomas J H Chen; Marlene Oscar-Berman; Margaret Madigan; Amanda Lh Chen; John A Bailey; Eric R Braverman; Mallory Kerner; John Giordano; Siobhan Morse; B William Downs; Roger L Waite; Frank Fornari; Zaher Armaly; Kenneth Blum
Journal:  Mol Neurobiol       Date:  2012-02-28       Impact factor: 5.590

5.  The dopamine D2 receptor gene and depressive and anxious symptoms in childhood: associations and evidence for gene-environment correlation and gene-environment interaction.

Authors:  Elizabeth P Hayden; Daniel N Klein; Lea R Dougherty; Thomas M Olino; Rebecca S Laptook; Margaret W Dyson; Sara J Bufferd; C Emily Durbin; Haroon I Sheikh; Shiva M Singh
Journal:  Psychiatr Genet       Date:  2010-12       Impact factor: 2.458

Review 6.  Alcohol: effects on neurobehavioral functions and the brain.

Authors:  Marlene Oscar-Berman; Ksenija Marinković
Journal:  Neuropsychol Rev       Date:  2007-09       Impact factor: 7.444

7.  Temporal sequence of comorbid alcohol use disorder and anorexia nervosa.

Authors:  Jessica H Baker; Laura M Thornton; Michael Strober; Harry Brandt; Steve Crawford; Manfred M Fichter; Katherine A Halmi; Craig Johnson; Ian Jones; Allan S Kaplan; Kelly L Klump; James E Mitchell; Janet Treasure; D Blake Woodside; Wade H Berrettini; Walter H Kaye; Cynthia M Bulik
Journal:  Addict Behav       Date:  2012-10-08       Impact factor: 3.913

8.  Combined neuroimaging, neurocognitive and psychiatric factors to predict alcohol consumption following treatment for alcohol dependence.

Authors:  Timothy C Durazzo; Stefan Gazdzinski; Ping-Hong Yeh; Dieter J Meyerhoff
Journal:  Alcohol Alcohol       Date:  2008-09-24       Impact factor: 2.826

9.  The many faces of affect: a multilevel model of drinking frequency/quantity and alcohol dependence symptoms among young adults.

Authors:  Jeffrey S Simons; Thomas A Wills; Dan J Neal
Journal:  J Abnorm Psychol       Date:  2014-06-16

10.  Relation of neural response to palatable food tastes and images to future weight gain: Using bootstrap sampling to examine replicability of neuroimaging findings.

Authors:  E Stice; S Yokum
Journal:  Neuroimage       Date:  2018-08-23       Impact factor: 6.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.